Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice

被引:144
|
作者
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
adherence; preexposure prophylaxis; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; SELF-REPORT; RISK; MEN; SEX; PREVENTION; INFECTION; TENOFOVIR; INTERVENTIONS;
D O I
10.1097/COH.0000000000000220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention.Recent findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies.SummaryPrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [21] PrEP prescription in indiana 2017-2022: Implications for clinical practice
    Carter, Gregory
    Tavares, Taran
    RESEARCH IN NURSING & HEALTH, 2024, 47 (01) : 49 - 59
  • [22] Lenacapavir for HIV PrEP: Narrative Review of Clinical Trials and Implications for Patient Access
    Goswami, Swarnali
    Veeramachaneni, Sai
    Masurkar, Prajakta P.
    CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2025, 17 (01)
  • [23] Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery
    Susanne Doblecki-Lewis
    Stephanie Cohen
    Albert Liu
    Current Treatment Options in Infectious Diseases, 2015, 7 (2) : 101 - 112
  • [24] The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082
    Geetha Beauchamp
    Sybil Hosek
    Deborah Donnell
    Kwun C. G. Chan
    Peter L. Anderson
    Bonnie J. Dye
    Nyaradzo Mgodi
    Linda-Gail Bekker
    Sinead Delany-Moretlwe
    Connie Celum
    AIDS and Behavior, 2024, 28 : 1512 - 1521
  • [25] The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082
    Beauchamp, Geetha
    Hosek, Sybil
    Donnell, Deborah
    Chan, Kwun C. G.
    Anderson, Peter L.
    Dye, Bonnie J.
    Mgodi, Nyaradzo
    Bekker, Linda-Gail
    Delany-Moretlwe, Sinead
    Celum, Connie
    AIDS AND BEHAVIOR, 2024, 28 (05) : 1512 - 1521
  • [26] PrEP (HIV pre-exposure prophylaxis) and its possibilities for clinical practice
    Nicholls, Emily Jay
    Rosengarten, Marsha
    SEXUALITIES, 2020, 23 (08) : 1327 - 1342
  • [27] PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
    Celum, Connie
    Hosek, Sybil
    Tsholwana, Mandisa
    Kassim, Sheetal
    Mukaka, Shorai
    Dye, Bonnie J.
    Pathak, Subash
    Mgodi, Nyaradzo
    Bekker, Linda-Gail
    Donnell, Deborah J.
    Wilson, Ethan
    Yuha, Krista
    Anderson, Peter L.
    Agyei, Yaw
    Noble, Heather
    Rose, Scott M.
    Baeten, Jared M.
    Fogel, Jessica M.
    Adeyeye, Adeola
    Wiesner, Lubbe
    Rooney, James
    Delany-Moretlwe, Sinead
    PLOS MEDICINE, 2021, 18 (06)
  • [28] Improving HIV pre-exposure prophylaxis (PrEP) adherence and retention in care: Process evaluation and recommendation development from a nationally implemented PrEP programme
    Macdonald, Jennifer
    Estcourt, Claudia S.
    Flowers, Paul
    Nandwani, Rak
    Frankis, Jamie
    Young, Ingrid
    Clutterbuck, Dan
    Dalrymple, Jenny
    Mcdaid, Lisa
    Steedman, Nicola
    Saunders, John
    PLOS ONE, 2023, 18 (10):
  • [29] Predictors of PrEP Drug Adherence Among Female Sex Workers in Mysore and Mandya, India: Insights From a Community-led PrEP Demonstration Project
    Rezapaul, Sushena
    Lazarus, Lisa
    Raviprakash, K. N.
    Halder, Partha
    Venugopal, M. S.
    Ramaiah, Manjula
    Lorway, Rob
    Becker, Marissa
    Mahmud, Salaheddin
    Moses, Stephen
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 91 - 91
  • [30] PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091)
    Poteat, T.
    Beauchamp, G.
    Marzinke, M. A.
    Gomez-Feliciano, K.
    Akingbade, B.
    Beck, J.
    Bell, I.
    Cummings, V.
    Emel, L.
    Franks, J.
    Jalil, E. M.
    Lake, J. E.
    Liu, A.
    Lucas, J.
    Mayer, K. H.
    Radix, A. E.
    Rooney, J.
    Spiegel, H.
    Watson, D. L.
    Zangeneh, S.
    Reisner, S. L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27